CliffBio
small molecule

GVOKE VIALDX

GLUCAGON

Loss of exclusivity—loss of exclusivity
CompanyXeris Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameGVOKE VIALDX
Active ingredientGLUCAGON
Strength1MG/0.2ML (1MG/0.2ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusDISCN

More from Xeris Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

GVOKE VIALDX patent cliff — loss of exclusivity — | CliffBio